BioAtla Statistics
Total Valuation
BioAtla has a market cap or net worth of $48.43 million. The enterprise value is $46.29 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioAtla has 58.79 million shares outstanding. The number of shares has increased by 16.89% in one year.
| Current Share Class | 58.79M |
| Shares Outstanding | 58.79M |
| Shares Change (YoY) | +16.89% |
| Shares Change (QoQ) | +0.41% |
| Owned by Insiders (%) | 10.24% |
| Owned by Institutions (%) | 14.48% |
| Float | 45.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.54
| Current Ratio | 0.54 |
| Quick Ratio | 0.46 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -105.08% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 3,164.45% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.06M |
| Employee Count | 61 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.83% in the last 52 weeks. The beta is 1.00, so BioAtla's price volatility has been similar to the market average.
| Beta (5Y) | 1.00 |
| 52-Week Price Change | -48.83% |
| 50-Day Moving Average | 0.79 |
| 200-Day Moving Average | 0.51 |
| Relative Strength Index (RSI) | 49.97 |
| Average Volume (20 Days) | 2,128,978 |
Short Selling Information
The latest short interest is 4.78 million, so 8.14% of the outstanding shares have been sold short.
| Short Interest | 4.78M |
| Short Previous Month | 4.52M |
| Short % of Shares Out | 8.14% |
| Short % of Float | 10.60% |
| Short Ratio (days to cover) | 3.66 |
Income Statement
| Revenue | n/a |
| Gross Profit | -46.73M |
| Operating Income | -65.69M |
| Pretax Income | -64.71M |
| Net Income | -64.71M |
| EBITDA | -65.11M |
| EBIT | -65.69M |
| Earnings Per Share (EPS) | -$1.15 |
Full Income Statement Balance Sheet
The company has $8.32 million in cash and $6.18 million in debt, giving a net cash position of $2.14 million or $0.04 per share.
| Cash & Cash Equivalents | 8.32M |
| Total Debt | 6.18M |
| Net Cash | 2.14M |
| Net Cash Per Share | $0.04 |
| Equity (Book Value) | -31.24M |
| Book Value Per Share | -0.53 |
| Working Capital | -8.31M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -57.07M |
| Capital Expenditures | n/a |
| Free Cash Flow | -57.07M |
| FCF Per Share | -$0.97 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioAtla does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.89% |
| Shareholder Yield | -16.89% |
| Earnings Yield | -133.60% |
| FCF Yield | -117.84% |
Analyst Forecast
The average price target for BioAtla is $1.00, which is 21.39% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.00 |
| Price Target Difference | 21.39% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -4.03% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioAtla has an Altman Z-Score of -60.91 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -60.91 |
| Piotroski F-Score | 1 |